Burning Rock Biotech (BNR) Operating Leases (2021 - 2023)

Burning Rock Biotech has reported Operating Leases over the past 3 years, most recently at $512494.5 for Q4 2023.

  • Quarterly results put Operating Leases at $512494.5 for Q4 2023, down 73.1% from a year ago — trailing twelve months through Dec 2023 was $512494.5 (down 73.1% YoY), and the annual figure for FY2023 was $520000.0, down 74.24%.
  • Operating Leases for Q4 2023 was $512494.5 at Burning Rock Biotech, down from $1.9 million in the prior quarter.
  • Over the last five years, Operating Leases for BNR hit a ceiling of $7.7 million in Q4 2021 and a floor of $512494.5 in Q4 2023.
  • Median Operating Leases over the past 3 years was $1.9 million (2022), compared with a mean of $3.4 million.
  • Biggest five-year swings in Operating Leases: tumbled 75.3% in 2022 and later tumbled 73.1% in 2023.
  • Burning Rock Biotech's Operating Leases stood at $7.7 million in 2021, then tumbled by 75.3% to $1.9 million in 2022, then tumbled by 73.1% to $512494.5 in 2023.
  • The last three reported values for Operating Leases were $512494.5 (Q4 2023), $1.9 million (Q4 2022), and $7.7 million (Q4 2021) per Business Quant data.